Notice of intent to solicit and negotiate a non-competitive modification for PCV 20 vaccine (Prevnar20)

Notice ID:

75D30121D1135501

Department/Ind. Agency:

HEALTH AND HUMAN SERVICES, DEPARTMENT OF

Sub-tier:

HEALTH AND HUMAN SERVICES, DEPARTMENT OF

Sub Command:

CDC OFFICE OF ACQUISITION SERVICES

Office:

CDC OFFICE OF ACQUISITION SERVICES

All Dates/Times are:

(utc-05:00) eastern standard time, new york, usa

Updated Published Date:

(utc-05:00) eastern standard time, new york, usa

Original Published Date:

0000-00-00 00:00:00

Original Response Date:

nov 24, 2021 04:30 pm est

Inactive Policy:

15 days after response date

Original Inactive Date:

dec 09, 2021

Initiative:

• None***--***

Product Service Code:

6505 - drugs and biologicals

NAICS Code:

325412 - pharmaceutical preparation manufacturing

Original Set Aside:

The Centers for Disease Control and Prevention (CDC) intends to solicit and negotiate a non-competitive modification to contract number 75D30121D11355, awarded to Pfizer Inc. (“Pfizer”) on June 17, 2021. This notice is provided in accordance with FAR 5.203(a). This contract is part of CDC’s 2021 Vaccines For Adults (VFA) indefinite-delivery indefinite-quantity contracts. This contract provides for the purchase of standard commercial adult vaccines for the National Center for Immunization and Respiratory Diseases’ (NCIRD) immunization awardees (the fifty state health departments, several large city program and current and former U.S. Territories) to support immunization programs as provided under Section 317(j) of the Public Health Service Act and Section 13631 of the Omnibus Budget Reconciliation Act of 1993. This modification will add a maximum of 400,000 doses of the PCV 20 vaccine (Prevnar20) for adults to the contract following the Advisory Committee on Immunization Practices (ACIP) approval and CDC recommendation in October 2021. The authority permitting other than full and open competition is FAR 6.302-1, "Only one responsible source and no other supplies or services will satisfy agency requirements." Pfizer is the only manufacturer with an FDA-approved license for PCV 20 at this time. All responsible sources my submit a capability statement, proposal, or quotation to Joshua Houston, Contract Specialist, at pkf5@cdc.gov, which shall be considered by the agency. The deadline for submissions is November 24, 2021, at 4:30pm Eastern time. The Government will review any/all information submitted to determine if other responsible sources exist that could provide this requirement. Information received in response to this announcement will be used solely for the purpose of determining whether to conduct a competitive procurement.

1600 CLIFTON ROAD

ATLANTA , GA 30333

USA

Primary Point of Contacts:

Joshua Houston

Secondary Point of Contact:

Pellumbeshe Hoxhaj